Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Sales | 16,322 | 14,381 | 60,290 | 5,650 | 623 |
| Cost of Goods | 82 | 1,247 | 30,051 | 149 | 50,000 |
| Gross Profit | 16,240 | 13,134 | 30,239 | 5,501 | -49,377 |
| Operating Expenses | 164,946 | 142,379 | 119,694 | 133,645 | 144,910 |
| Operating Income | -148,624 | -128,998 | -89,404 | -127,995 | -194,287 |
| Interest Expense | 8,448 | 8,538 | 3,017 | 2,282 | 3,767 |
| Other Income | 1,581 | -191 | -55,160 | -65,294 | -21,137 |
| Pre-tax Income | -155,491 | -137,727 | -147,581 | -195,571 | -219,191 |
| Income Tax | 486 | 1,208 | N/A | N/A | N/A |
| Net Income Continuous | -155,977 | -138,935 | -147,933 | -195,571 | -219,191 |
| Net Income | $-155,977 | $-138,935 | $-147,933 | $-195,571 | $-219,191 |
| EPS Basic Total Ops | -1.46 | -1.42 | -1.52 | -2.28 | -2.72 |
| EPS Basic Continuous Ops | -1.46 | -1.42 | -1.52 | -2.28 | -2.72 |
| EPS Diluted Total Ops | -1.46 | -1.42 | -1.52 | -2.28 | -2.72 |
| EPS Diluted Continuous Ops | -1.46 | -1.42 | -1.52 | -2.28 | -2.72 |
| EBITDA(a) | $-134,800 | $-128,494 | $-87,693 | $-127,579 | $-193,520 |